All News

EULAR19.abstract.jpg (keep)

EULAR 2026: Industry Press Releases

Jack Cush, MD

Pharmaceutical companies are presenting pivotal clinical trial results and key data analyses at the EULAR 2026 Congress (June 3–6, London). Below is a summary of their most important studies — many of which are registration-enabling or will directly shape treatment decisions in rheumatic diseases.

Read Article
PsA.Xray_.Erosion.Cup_.jpg

Guselkumab gets FDA Nod for X-ray Protection

Jack Cush, MD

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's supplemental Biologics License (sBLA) to include evidence in the guselkumab (Tremfya) label for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis (PsA). 

Read Article
RheumNow Podcast square

Quiz Talk (5.22.2026)

Jack Cush, MD

Dr. Jack Cush talks of birthdays, Quizzes and journal articles this week on the podcast.

Read Article
H2H.BKZ.RZB

BE BOLD Week 16 data - Bimekizumab vs. Risankizumab in PsA

Jack Cush, MD

UCB has released the Week 16 results from BE BOLD trial that will be presented at EULAR 2026 in London on Saturday, June 6.

Read Article
pediatric eye uveitis

Immune-Mediated Inflammatory Diseases Following Uveitis

Jack Cush, MD

A Korean insurance claims data study showed children and adolescents diagnosed with uveitis have a 7-fold increased risk of developing an immune-mediated inflammatory disorder (IMID).

Read Article
RheumNow Podcast square

Influential Rheumatoid Factors (5.8.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com

Read Article
Not all "difficult-to-treat" #PsA definitions are equal. Real-world DEPAR cohort (n=885): 20% met GRAPPA complex-to-manage vs only 4% EULAR difficult-to-manage criteria. Definition choice determines who gets identified, and who gets left behind. @RheumNow #EULAR2026 POS0446

Jiha Lee JihaRheum ( View Tweet)

IL-23i vs IL-17i in PsABIOnd (n=1,141): 12mo persistence (~77%), joint/skin response, MDA, and PROs similar across both. GUS matched IL-17i despite treating more biologic-experienced pts (15% vs 8% on 4th-line). GI AEs higher with IL-17i (11% vs 7%). @RheumNow #EULAR2026 POS0045

Jiha Lee JihaRheum ( View Tweet)

What’s new in (WIN) PsA session. A preview of the BE BOLD study: Bimekizumab vs risankizumab on ACR50 in active #PsA 49.1% vs 38.4% (p=0.008). The first head-to-head biologic trial to show joint superiority in PsA. Dual IL-17A/F blockade important. Abstr #LB0001 @RheumNow

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

What’s in the pipeline for #psoriatic_arthritis treatment? A special focus on Tyk2 inhibitors WIN session at #EULAR2026 @RheumNow https://t.co/dDJtmdx9xU

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
What is new in PsA? Dennis McGonagle's take at #EULAR2026 -a strong year for discovery in mechanisms of transition from PSO to PsA -publication of the first single cell atlas Enthesis -Better understanding of VTE mechanisms in JAKi in PsA -clinical aspects of Axial involvement https://t.co/v9cfn1y4fH

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
DERM on RheumNow PODCAST (May 2026) The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, and other CTD skin disorders. Dermatology drugs, biologics, JAKs - their use, efficacy, and https://t.co/0AEAxadBFT
Dr. John Cush RheumNow ( View Tweet)
Congratulations to Professor Dennis McGonagle for being awarded the prestigious Heberden Oration Award at the 2026 British Society for Rheumatology (BSR) Conference. https://t.co/TOG5Y9tNrW https://t.co/3aumO6Z3A9

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has approved that guselkumab (Tremfya) for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis (PsA) https://t.co/KwcECQpSz1 https://t.co/pSoK930FAX

Links:

Dr. John Cush RheumNow ( View Tweet)
BE BOLD Week 16 data - Bimekizumab vs. Risankizumab in PsA UCB has released the Week 16 results from BE BOLD trial that will be presented at EULAR 2026 in London on Saturday, June 6. This head-to-head trial demonstrates that at week 16, bimekizumab (BKZ) yielded superior ACR50 https://t.co/VVBaNdWIuQ
Dr. John Cush RheumNow ( View Tweet)
Best JAKi? Italian Observational BIRRA Cohort study of 170 #PsA pts Rx w/ UPA or TOFA found no significance in 6 mos (86 vs 78%) or 12 mos (68 v 60%) retention. Persistence lower in pts Concomitant or later csDMARDs. https://t.co/vtSrO9orh4

Links:

Dr. John Cush RheumNow ( View Tweet)

Another IL-17A inhibitor (Vunakizumab) for active Ankylosing Spondylitis Vunakizumab, a novel anti–interleukin (IL) 17A monoclonal antibody, was studied in patients with active radiographic axial spondyloarthritis [r-axSpA] and found to be effective and tolerable. https://t.co/4WMLbcPLOs
Dr. John Cush RheumNow ( View Tweet)
Meet the RheumNow #EULAR2026 Reporting Team Delivering real-time insights from the forefront of rheumatology: 🩺 Dr. Antoni Chan (@synovialjoints) 🩺 Dr. Mrinalini Dey (@DrMiniDey) 🩺 Dr. Jiha Lee (@JihaRheum) 🩺 Dr. Aurelie Najm (@AurelieRheumo) 🩺 Dr. Janet Pope https://t.co/zpIeGWpL6P
Dr. John Cush RheumNow ( View Tweet)
True or False: HLA-B27 positivity in psoriatic arthritis is associated with earlier disease onset and a higher prevalence of axial involvement. Put your knowledge to the test in this week's RheumIQ quiz at https://t.co/KVK8J2iaFQ https://t.co/SZZqaNvO2Z

Links:

Dr. John Cush RheumNow ( View Tweet)
EMA/European Commission has aproved Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults https://t.co/Fv9DON1AvB https://t.co/Li79tKzMxK

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×